What can be expected from the next quarterly profit report from Moderna

Photo of author

By [email protected]


Moderna Inc Meds -By Ascannio via Shutterstock
Moderna Inc Meds -By Ascannio via Shutterstock

At a value of $ 13 billion by the market, Cambridge, Massachusetts, is MRNA, as a pharmaceutical company for the clinical stage. It focuses on the discovery and development of RNA (flexible) treatments and vaccines to treat autoimmune conditions, infectious diseases, immune diseases, rare diseases, and cardiovascular diseases.

The health care pioneer is expected to announce the results of the second quarter on Thursday, August 7. Before this event, analysts expect Moderna to take a loss of $ 2.97 per share, 10.8 % less than $ 3.33 per share in the previous quarter. In a positive note, the company has exceeded the lower street estimates in each of the past four quarters.

For the full fiscal year 2025, analysts expect that the company will report a loss of $ 9.81 per share, 10.6 % more than $ 8.87 per share in 2024. While in the fiscal year 2026, it is expected to lose its losses by 29.4 % on an annual basis to $ 6.93 per share.

www.barchart.com
www.barchart.com

The arbitrary marina has decreased by 72.6 % over the past 52 weeks, dramatically behind the S&P 500 index gains ($ SPX) by 12.1 % and the SPDR health care box (XLV) decreased by 8.3 % during the same time frame.

www.barchart.com
www.barchart.com

Midena shares rose to the highest level ever at $ 497.49 in August 2021, driven by increasing demand for Covid-19 vaccines. However, since then, the stock has continued to erode the wealth of investors.

His share decreased by 5.3 % after the release of the mixed Q1 2025 results on May 1. The company has reported revenues of $ 108 million, a decrease of 35.3 % year on year, and the US -Street forecast of $ 127 million was lost. The decrease in revenue was primarily due to the low net products sales, caused by low vaccination rates compared to the same period last year. Meanwhile, the summary of the matter came with a loss of $ 2.52 per share, slightly better than street expectations.

The arrow contains the “Hold” category in general. Of the 26 analysts covering stocks, opinions include three “strong purchases”, 19 “Holds”, one “mild sale”, and three “strong sale”. As of writing, the stock is significantly traded less than the average price of $ 42.86.

On the date of publication, Aditya Sarawi did not have positions (either directly or indirectly) in any of the securities mentioned in this article. All information and data in this article are only for media purposes. This article was originally published on Barchart.com



https://media.zenfs.com/en/barchart_com_477/e07a98d38106a7710d2a8edf7a45e8c7

Source link

Leave a Comment